1155 studies found for:    Doxorubicin (liposomal) OR Doxil[TREATMENT] AND HIV [CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
Doxorubicin (liposomal) OR Doxil[TREATMENT] AND HIV [CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Conditions: Cancer;   Carcinoma;   Fallopian Tube Cancer;   Gynecological Malignancies;   Metastases;   Oncology;   Ovarian Cancer;   Solid Tumors;   Tumors
Interventions: Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin;   Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin;   Drug: B1: AMG 386 10 mg/kg + Topotecan;   Drug: B3: AMG 386 15mg/kg + Topotecan
2 Terminated MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)
Condition: Ovarian Cancer
Intervention: Drug: MK-4827 + pegylated liposomal doxorubicin
3 Suspended Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas
Conditions: Solid Tumors;   Lymphomas
Interventions: Drug: Recombinant human TNF-α;   Drug: Liposomal doxorubicin;   Drug: Caelyx
4 Completed Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Carcinoma
Interventions: Drug: Pazopanib;   Drug: Doxil
5 Completed A Study of Liposomal Doxorubicin With or Without IMC-3G3 in Platinum-refractory or Resistant Advanced Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Biological: IMC-3G3;   Drug: liposomal doxorubicin
6 Terminated
Has Results
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
Condition: Refractory Multiple Myeloma
Interventions: Drug: liposomal doxorubicin;   Drug: bortezomib;   Drug: dexamethasone;   Drug: cyclophosphamide
7 Withdrawn Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Condition: Breast Cancer
Interventions: Drug: Liposomal Doxorubicin;   Drug: Seliciclib
8 Recruiting Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Drug: Veliparib
9 Active, not recruiting Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
Interventions: Drug: Bortezomib;   Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride
10 Unknown  Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Interventions: Drug: Liposomal doxorubicin;   Drug: Cisplatin
11 Completed Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: sargramostim;   Drug: methotrexate;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: vincristine sulfate
12 Completed Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Condition: Sarcoma
Intervention: Drug: temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
13 Completed Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
Conditions: Primary Peritoneal Carcinoma;   Epithelial Ovarian Carcinoma;   Neoplasms, Ovarian;   Fallopian Tube Cancer
Intervention: Drug: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
14 Recruiting Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma
Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
15 Completed Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement
Condition: Advanced Cancer
Interventions: Drug: Cisplatin;   Drug: Liposomal Doxorubicin
16 Completed Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma
Condition: AIDS-related Kaposi Sarcoma
Interventions: Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
17 Active, not recruiting Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Veliparib
18 Withdrawn A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Liposomal Doxorubicin/Melphalan/Bortezomib
19 Recruiting EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Biological: EGEN-001;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis
20 Unknown  Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Drug: PLD and Carboplatin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years